Sanofi $SNY Shares Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky grew its stake in shares of Sanofi (NASDAQ:SNY) by 8.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 443,390 shares of the company’s stock after purchasing an additional 34,100 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Sanofi were worth $20,928,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Caprock Group LLC acquired a new position in Sanofi during the 3rd quarter worth approximately $1,347,000. Assetmark Inc. raised its holdings in shares of Sanofi by 25.0% in the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after purchasing an additional 71,356 shares during the period. Thrivent Financial for Lutherans lifted its stake in Sanofi by 10,152.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock valued at $103,846,000 after purchasing an additional 2,178,647 shares during the last quarter. NewEdge Wealth LLC grew its holdings in Sanofi by 63.1% during the third quarter. NewEdge Wealth LLC now owns 67,303 shares of the company’s stock worth $3,298,000 after purchasing an additional 26,035 shares during the period. Finally, Willis Investment Counsel raised its stake in Sanofi by 11.3% in the third quarter. Willis Investment Counsel now owns 556,700 shares of the company’s stock valued at $26,276,000 after buying an additional 56,500 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

Shares of SNY stock opened at $46.47 on Wednesday. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The business’s 50-day moving average price is $47.49 and its 200-day moving average price is $48.55. The firm has a market capitalization of $113.34 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 1.23 and a beta of 0.45.

Analysts Set New Price Targets

A number of research firms recently weighed in on SNY. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Sanofi currently has an average rating of “Hold” and an average price target of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.